Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for pancreatic cancer: experimental drug quemliclustat in Late-Stage trial

NCT ID NCT06608927

Disease control Sponsor: Arcus Biosciences, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 03, 2026 · Updated 5 times

Summary

This Phase 3 trial is testing whether adding an experimental drug called quemliclustat to standard chemotherapy (nab-paclitaxel and gemcitabine) helps people with metastatic pancreatic cancer live longer. About 610 participants who have not yet received treatment for their advanced cancer will be randomly assigned to receive either the experimental drug or a placebo, alongside chemotherapy. The main goal is to compare overall survival between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
quemliclustat (an experimental drug) combined with chemotherapy (nab-paclitaxel and gemcitabine)
What this could lead to
If it works, this could provide a new treatment option that extends survival for people with metastatic pancreatic cancer.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet known. The experimental drug may not improve survival and could cause additional side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 610 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Nov 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have histologically or cytologically confirmed PDAC that is metastatic. * Have not been previously treated for PDAC in the metastatic setting. 1. Prior neoadjuvant and/or adjuvant therapy for PDAC is permitted if completed at least 12 months before randomization. 2. Prior palliative radiotherapy is allowed if completed at least 2 weeks prior to randomization and AEs have resolved to Grade 1 or less before randomization. 3. Prior and/or placement of a biliary stent/tube is permitted if any treatment-related AEs have improved to Grade ≤ 1 and the patient is not exhibiting any signs/symptoms of biliary obstruction. * Eastern Cooperative Oncology Group PS of 0 to 1. * At least 1 target lesion measurable by computed tomography (CT)/magnetic resonance imaging (MRI) per RECIST v1.1. not within a field of prior radiation therapy. Exclusion Criteria: * Previously treated for locally advanced, unresectable PDAC. * History of brain metastases or leptomeningeal metastases. * Prior treatment with a CD73 antagonist or inhibitor. * Underlying medical conditions that, in the investigator or sponsor's opinion, will make the administration of study-specified therapy hazardous NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic ductal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic pancreatic ductal adenocarcinoma

Contacts and locations

Locations

  • Research Site

    Phoenix, Arizona, 85054, United States

  • Research Site

    Tucson, Arizona, 85724, United States

  • Research Site

    La Jolla, California, 92093, United States

  • Research Site

    Los Alamitos, California, 90720, United States

  • Research Site

    Los Angeles, California, 90033-5315, United States

  • Research Site

    Roseville, California, 95661, United States

  • Research Site

    San Francisco, California, 94158, United States

  • Research Site

    Santa Monica, California, 90404, United States

  • Research Site

    Denver, Colorado, 80218, United States

  • Research Site

    New Haven, Connecticut, 06520, United States

  • Research Site

    Jacksonville, Florida, 32224-1865, United States

  • Research Site

    Miami, Florida, 33176, United States

  • Research Site

    Atlanta, Georgia, 30318, United States

  • Research Site

    Atlanta, Georgia, 30322, United States

  • Research Site

    Arlington Heights, Illinois, 60005, United States

  • Research Site

    Chicago, Illinois, 60611, United States

  • Research Site

    Indianapolis, Indiana, 46202, United States

  • Research Site

    Wichita, Kansas, 67208, United States

  • Research Site

    Baton Rouge, Louisiana, 70809, United States

  • Research Site

    Ann Arbor, Michigan, 48109, United States

  • Research Site

    Grand Rapids, Michigan, 49503, United States

  • Research Site

    Minneapolis, Minnesota, 55404, United States

  • Research Site

    Rochester, Minnesota, 55905, United States

  • Research Site

    Hattiesburg, Mississippi, 39401, United States

  • Research Site

    Kansas City, Missouri, 64111, United States

  • Research Site

    Omaha, Nebraska, 68105, United States

  • Research Site

    New Brunswick, New Jersey, 08903-2681, United States

  • Research Site

    Buffalo, New York, 14263, United States

  • Research Site

    New York, New York, 10016, United States

  • Research Site

    New York, New York, 10032, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    New York, New York, 10128, United States

  • Research Site

    Rochester, New York, 14642, United States

  • Research Site

    Cleveland, Ohio, 44106, United States

  • Research Site

    Oklahoma City, Oklahoma, 73104, United States

  • Research Site

    Philadelphia, Pennsylvania, 19111-2497, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15232, United States

  • Research Site

    Nashville, Tennessee, 37232, United States

  • Research Site

    Austin, Texas, 78705, United States

  • Research Site

    Dallas, Texas, 75246, United States

  • Research Site

    Dallas, Texas, 75390, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    San Antonio, Texas, 78240, United States

  • Research Site

    Webster, Texas, 77598, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Seattle, Washington, 98101, United States

  • Research Site

    Spokane, Washington, 99208, United States

  • Research Site

    Vancouver, Washington, 98684, United States

  • Research Site

    Madison, Wisconsin, 53792, United States

  • Research Site

    Camperdown, Australia

  • Research Site

    Clayton, Australia

  • Research Site

    Murdoch, Australia

  • Research Site

    Wollongong, Australia

  • Research Site

    Salzburg, Austria

  • Research Site

    Sankt Pölten, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Anderlecht, Belgium

  • Research Site

    Bonheiden, Belgium

  • Research Site

    Kortrijk, Belgium

  • Research Site

    Ottawa, Canada

  • Research Site

    Sherbrooke, Canada

  • Research Site

    Toronto, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Nový Jičín, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Dijon, France

  • Research Site

    Lille, France

  • Research Site

    Lyon, France

  • Research Site

    Poitiers, France

  • Research Site

    Villejuif, France

  • Research Site

    Bochum, Germany

  • Research Site

    Frankfurt am Main, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Hanover, Germany

  • Research Site

    Heilbronn, Germany

  • Research Site

    Magdeburg, Germany

  • Research Site

    Riesa, Germany

  • Research Site

    Ulm, Germany

  • Research Site

    Würzburg, Germany

  • Research Site

    Bologna, Italy

  • Research Site

    Cremona, Italy

  • Research Site

    Florence, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Modena, Italy

  • Research Site

    Padova, Italy

  • Research Site

    Piacenza, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Rozzano, Italy

  • Research Site

    Torrette, Italy

  • Research Site

    Verona, Italy

  • Research Site

    Kashiwa-shi, Japan

  • Research Site

    Kōtō City, Japan

  • Research Site

    Osaka, Japan

  • Research Site

    Tokyo, Japan

  • Research Site

    Toyama, Japan

  • Research Site

    Ube, Japan

  • Research Site

    Yokohama, Japan

  • Research Site

    Hwasun, South Korea

  • Research Site

    Seongnam, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Barcelona, Spain

  • Research Site

    Elche, Spain

  • Research Site

    Girona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Pamplona, Spain

  • Research Site

    Vigo, Spain

  • Research Site

    Zaragoza, Spain

  • Research Site

    Birmingham, United Kingdom

  • Research Site

    Cottingham, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.